Evidence map›Paper›PMID 32285549›Full record

ArticleJournal of cellular and molecular medicine2020

ENO1-targeted superparamagnetic iron oxide nanoparticles for detecting pancreatic cancer by magnetic resonance imaging.

Lei Wang, Hang Yin, Rongrong Bi, Guo Gao, Kaicheng Li, Hai-Lin Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  13. Article
  14. Article
  15. Theranostic nanoparticles for detection and treatment of pancreatic cancer.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Lei WangDepartment of Gastroenterology, The Ninth People's Hospital Affiliated to the School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Hang YinDepartment of Gastroenterology, The Ninth People's Hospital Affiliated to the School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Rongrong BiDepartment of Pulmonary, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Guo GaoDepartment of Instrument Science and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of the Ministry of Education, Institute of Nano Biomedicine and Engineering, Shanghai Jiao Tong University, Shanghai, China.
Kaicheng LiDepartment of Radiology, The Ninth People's Hospital Affiliated to the School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Hai-Lin LiuDepartment of Gastroenterology, The Ninth People's Hospital Affiliated to the School of Medicine, Shanghai Jiaotong University, Shanghai, China.ORCID 0000-0002-0172-2449
Shanghai Ninth People's Hospital · CNShanghai Jiao Tong University · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate in vitro magnetic resonance imaging (MRI) of PDAC using ENO1-targeted superparamagnetic iron oxide nanoparticles and xenograft models. Expression level and location of ENO1 protein in pancreatic cancer cell lines of CFPAC-1 and MiaPaCa-2 were detected by Western blotting, flow cytometry and confocal microscopy. Dex-g-PCL/SPIO nanoparticles targeting ENO1 were constructed with ENO1 antibody and characterized by MRI. In addition, ENO1-Dex-g-PCL/SPIO nanoparticles were tested to assess their efficacy on the detection of PDAC using in vitro and in vivo MRI. The results showed that ENO1 was expressed in both human PDAC cell lines of CFPAC-1 and MiaPaCa-2, demonstrating that the localization of cytoplasm and membrane was dominant. It was confirmed that ENO1 antibody was connected to the SPIO surface in ENO1-Dex-g-PCL/SPIO nanoparticles. The nanoparticles had satisfactory superparamagnetism and significantly enhance the detection of PDAC by in vivo and in vitro MRI. In conclusion, ENO1 can serve as a membrane protein expressed on human PDAC cell lines. ENO1-targeted SPIO nanoparticles using ENO1 antibody can increase the efficiency of detection of PDAC by in vitro and in vivo MRI.

Indexed as

Magnetic Resonance ImagingAnimalsBiomarkers, TumorCell Line, TumorDextransDNA-Binding ProteinsHumansMagnetic Iron Oxide NanoparticlesMaleMice, Inbred BALB CMice, NudePancreatic NeoplasmsPhosphopyruvate HydratasePolyestersTumor Suppressor ProteinsBiomarkers, Tumordextran-g-poly(epsilon-caprolactone)DextransDNA-Binding ProteinsENO1 protein, humanPhosphopyruvate HydratasePolyestersTumor Suppressor Proteinsdiagnosismolecular imagingpancreatic neoplasmsphosphopyruvate hydratase

Identifiers

PMID32285549
PMCPMC7214157
OpenAlexW3015713168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.